Trial Profile
Open-Label Roll-Over Study to Assess the Long-Term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- 24 Jan 2024 Status changed from active, no longer recruiting to completed.
- 24 Oct 2019 Planned End Date changed from 30 Sep 2020 to 30 Sep 2024.
- 24 Oct 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Sep 2024.